[New Zimbabwe] As soon as her husband got wind of the nature of her sickness, he left, leaving her to deal with the unfavourable and very difficult conditions associated with cancer, anal cancer for that matter.
In this study, we investigate the effect of the local, topical application of a BEZ235 on tumor-free survival, histopathology, PI3K/mTOR, and autophagy. The rationale for investigating a topical formulation is the localized nature of anal dysplasia/cancer and the goal for creating a clinically translatable formulation to decrease anal carcinogenesis. In this study, HPV transgenic mice were given no treatment, topical BEZ235, topical 7,12 dimethylbenz[a]anthracene (DMBA) (carcinogen), or both topical DMBA + BEZ235. Mice were assessed for tumor development and treatment-related toxicities. Tissue was evaluated for histology,…
ConclusionsRT dose intensification appears safe with acceptable compliance, acute toxicity and PROs at 6 months. Data Monitoring Committee approved phase II with no treatment schedule changes but included a 6 month clinician toxicity assessment. Phase II will open in June 2019.Clinical trial identificationISRCTN88455282.Legal entity responsible for the studyUniversity of Leeds.FundingCancer Research UK.DisclosureAll authors have declared no conflicts of interest.
ConclusionsPEN-866 appears well tolerated with an expected adverse event profile and preliminary evidence of antitumor activity. PEN-866 will be evaluated in phase 2a expansion cohorts (NCT03221400).Clinical trial identificationNCT03221400 July 18, 2017.Legal entity responsible for the studyTarveda Therapeutics, Inc.FundingTarveda Therapeutics, Inc.DisclosureJ.C. Bendell: Research grant / Funding (institution): Tarveda Therapeutics; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses, Advisory/Consultancy to Institution: Gilead; Advisory / Consultancy, Research grant / Funding …
We extracted image features from serial 18F-labeled fluorodeoxyglucose (FDG) positron emission tomography (PET) / computed tomography (CT) scans of anal cancer patients for the prediction of tumor recurrence after chemoradiation therapy (CRT). Seventeen patients (4 recurrent and 13 non-recurrent) underwent three PET/CT scans at baseline (Pre-CRT), in the middle of the treatment (Mid-CRT) and post-treatment (Post-CRT) were included. For each patient, Mid-CRT and Post-CRT scans were aligned to Pre-CRT scan. Comprehensive image features were extracted from CT and PET (SUV) images within manually delineated gross tumor volume,…
DISCUSSION: With the current increasing use of capecitabine, recognizing this agent as a potential risk factor for cardiac-related events is important.
PMID: 31545935 [PubMed – in process]
Condition: Anal Cancer Interventions: Device: special tampon with a diameter of 28mm; Device: standard tampon with a diameter of 12-13mm Sponsor: Juergen Debus Not yet recruiting
Condition: Anal Cancer Interventions: Behavioral: Practice Self-/Companion Exams; Behavioral: Control Arm Sponsors: Medical College of Wisconsin; University of Chicago; Baylor College of Medicine; The University of Texas Health Science Center, Houston; Gordon Crofoot MD PA Not yet recruiting